Stocks Overview

LAST PRICE
2.1400
TODAY'S CHANGE (%)
Trending Down-0.2500 (-10.4603%)

Bid / Lots
2.0600/ 5
Ask / Lots
2.4500/ 5
Open / Previous Close
2.3700 / 2.3900
Day Range
Low 2.1300
High 2.4000
52 Week Range
Low 0.6840
High 6.0400
Volume
502,841
average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TSX Comp
TSX Venture
DJIA
S&P 500
NASDAQ

Price Comparison Graph. See accessible table below

1 Day Comparison Chart Accessibility Table. Friday's close: 2.39
Time	Volume	ADCT
09:32 ET	17554	2.4
09:33 ET	4858	2.33
09:35 ET	1300	2.335
09:37 ET	1513	2.3551
09:42 ET	22086	2.33
09:44 ET	4804	2.33
09:46 ET	1600	2.31
09:48 ET	5142	2.3091
09:50 ET	2349	2.31
09:51 ET	400	2.32
09:53 ET	500	2.31
09:55 ET	1240	2.3
09:57 ET	1700	2.2916
10:00 ET	3289	2.295
10:02 ET	3593	2.29
10:04 ET	2717	2.31
10:06 ET	604	2.325
10:08 ET	202	2.3199
10:09 ET	410	2.315
10:11 ET	2924	2.33
10:13 ET	322	2.33
10:15 ET	11591	2.305
10:18 ET	1069	2.31
10:20 ET	1300	2.315
10:22 ET	9516	2.31
10:24 ET	532	2.3108
10:26 ET	927	2.315
10:27 ET	2216	2.32
10:29 ET	3800	2.319
10:31 ET	1105	2.32
10:33 ET	1049	2.32
10:36 ET	16896	2.33
10:38 ET	2574	2.33
10:40 ET	4100	2.3108
10:42 ET	880	2.3
10:44 ET	4072	2.2862
10:45 ET	5955	2.28
10:47 ET	300	2.275
10:49 ET	433	2.275
10:51 ET	500	2.27
10:54 ET	2455	2.251
10:56 ET	500	2.255
10:58 ET	300	2.255
11:00 ET	339	2.255
11:02 ET	400	2.255
11:03 ET	2785	2.255
11:05 ET	1000	2.2542
11:07 ET	1200	2.255
11:09 ET	2950	2.25
11:12 ET	100	2.2563
11:14 ET	600	2.255
11:16 ET	900	2.255
11:18 ET	100	2.255
11:20 ET	300	2.255
11:21 ET	300	2.26
11:23 ET	700	2.255
11:25 ET	290	2.255
11:27 ET	3500	2.255
11:30 ET	6068	2.255
11:32 ET	800	2.25
11:34 ET	100	2.255
11:36 ET	1181	2.25
11:38 ET	400	2.25
11:41 ET	100	2.25
11:43 ET	100	2.255
11:45 ET	100	2.25
11:48 ET	1000	2.255
11:50 ET	300	2.255
11:52 ET	1424	2.24
11:54 ET	11249	2.265
11:56 ET	2036	2.265
11:57 ET	200	2.265
11:59 ET	657	2.265
12:01 ET	1013	2.26
12:06 ET	5047	2.275
12:08 ET	1200	2.265
12:10 ET	200	2.265
12:12 ET	993	2.27
12:14 ET	300	2.265
12:15 ET	2180	2.2757
12:17 ET	8165	2.27
12:19 ET	2200	2.27
12:21 ET	200	2.27
12:24 ET	457	2.265
12:26 ET	951	2.275
12:28 ET	430	2.275
12:30 ET	300	2.275
12:32 ET	911	2.275
12:33 ET	1000	2.2701
12:35 ET	300	2.275
12:37 ET	330	2.275
12:39 ET	1140	2.2798
12:42 ET	100	2.275
12:44 ET	600	2.275
12:46 ET	1876	2.255
12:48 ET	100	2.255
12:50 ET	200	2.255
12:51 ET	650	2.255
12:53 ET	4000	2.23
12:55 ET	2445	2.235
12:57 ET	2280	2.235
01:00 ET	579	2.24
01:02 ET	650	2.235
01:04 ET	400	2.23
01:06 ET	300	2.235
01:08 ET	530	2.23
01:09 ET	200	2.235
01:11 ET	300	2.235
01:13 ET	200	2.24
01:15 ET	1036	2.225
01:18 ET	8133	2.205
01:20 ET	400	2.205
01:22 ET	200	2.205
01:24 ET	150	2.205
01:26 ET	200	2.205
01:27 ET	700	2.205
01:29 ET	200	2.205
01:31 ET	500	2.205
01:33 ET	100	2.205
01:36 ET	3731	2.205
01:38 ET	366	2.205
01:40 ET	425	2.2
01:44 ET	6352	2.2
01:45 ET	756	2.205
01:47 ET	5451	2.205
01:49 ET	1098	2.2091
01:51 ET	200	2.205
01:54 ET	618	2.205
01:56 ET	1200	2.2
01:58 ET	300	2.205
02:00 ET	200	2.2
02:02 ET	1500	2.2
02:03 ET	2118	2.2
02:05 ET	594	2.2
02:07 ET	1162	2.2
02:09 ET	7415	2.2
02:12 ET	1200	2.205
02:14 ET	400	2.2
02:16 ET	300	2.2
02:18 ET	600	2.2088
02:20 ET	300	2.21
02:21 ET	400	2.21
02:23 ET	6000	2.2
02:25 ET	34993	2.175
02:27 ET	1600	2.17
02:30 ET	2000	2.15
02:32 ET	3100	2.16
02:34 ET	11674	2.1601
02:36 ET	500	2.1601
02:38 ET	728	2.165
02:39 ET	300	2.165
02:41 ET	650	2.165
02:43 ET	3724	2.175
02:45 ET	3845	2.185
02:48 ET	560	2.18
02:50 ET	1169	2.1885
02:52 ET	500	2.18
02:54 ET	400	2.18
02:56 ET	744	2.175
02:57 ET	1400	2.175
02:59 ET	300	2.175
03:01 ET	300	2.17
03:03 ET	900	2.17
03:06 ET	300	2.17
03:08 ET	200	2.17
03:10 ET	532	2.175
03:12 ET	1425	2.175
03:14 ET	200	2.175
03:15 ET	2300	2.17
03:17 ET	200	2.17
03:19 ET	200	2.17
03:21 ET	1300	2.175
03:24 ET	645	2.175
03:26 ET	1936	2.175
03:28 ET	900	2.17
03:30 ET	900	2.175
03:32 ET	850	2.175
03:33 ET	300	2.17
03:35 ET	1540	2.165
03:37 ET	600	2.165
03:39 ET	654	2.165
03:42 ET	100	2.16
03:44 ET	900	2.1601
03:46 ET	1900	2.16
03:48 ET	1644	2.15
03:50 ET	500	2.15
03:51 ET	1700	2.155
03:53 ET	4930	2.14
03:55 ET	900	2.13
03:57 ET	1139	2.135
04:00 ET	48189	2.14

Data delayed at least 15 minutes.

Nov 8, 2024
- DJ ADC Therapeutics Initiated at Overweight by Stephens & Co., from 7:18AM ET on Friday Nov 08, 2024 by Dow Jones
  7:18AM ET on Friday Nov 08, 2024 by Dow Jones
Nov 7, 2024
- Press Release: ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational Update, from 7:30AM ET on Thursday Nov 07, 2024 by Dow Jones
  7:30AM ET on Thursday Nov 07, 2024 by Dow Jones
- ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational Update, from 7:30AM ET on Thursday Nov 07, 2024 by Dow Jones
  7:30AM ET on Thursday Nov 07, 2024 by Dow Jones
Nov 5, 2024
- ADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual Meeting, from 9:48AM ET on Tuesday Nov 05, 2024 by Dow Jones
  9:48AM ET on Tuesday Nov 05, 2024 by Dow Jones
Nov 4, 2024
- ADC Therapeutics to Present at November Investor Conferences, from 7:15AM ET on Monday Nov 04, 2024 by Dow Jones
  7:15AM ET on Monday Nov 04, 2024 by Dow Jones

0 New Today

Industry Peers Overview Table
Company sortable	Market Cap sortable	P/E Ratio (TTM) sortable	EPS Growth (5yr) sortable
United StatesADCT ADC Therapeutics SA	231.1M	-0.9x	---
United StatesFATE Fate Therapeutics Inc	230.0M	-1.4x	---
United StatesEDIT Editas Medicine Inc	219.6M	-1.0x	---
United StatesPSTX Poseida Therapeutics Inc	268.1M	-4.2x	---
United StatesPSNL Personalis Inc	274.8M	-2.1x	---
United StatesMGNX MacroGenics Inc	224.1M	-2.2x	---
As of 2024-11-18

ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.

Contact Information

Headquarters: Biopole, route de la Corniche 3BEPALINGES, Switzerland 1066
Phone: ---
Fax: ---

Executives

Non-Executive Chairman of the Board: Ron Squarer
Chief Executive Officer, Director: Ameet Mallik
Chief Financial Officer: Jose Carmona
Chief Scientific Officer: Patrick Van Berkel
Chief Legal Officer: Peter Graham

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Skip section

INK Company InsiderDetailed daily analysis of insider activity and holdings for stocks and income trusts listed in Canada, based on filings from SEDI®.

Fundamentals Table

Market Cap	$231.1M
Revenue (TTM)	$70.7M
Shares Outstanding	96.7M
ADC Therapeutics SA does not pay a dividend.


Beta	1.58
EPS	$-2.40
Book Value	$-1.80
P/E Ratio	-0.9x
Price/Sales (TTM)	3.3
Price/Cash Flow (TTM)	---
Operating Margin	-195.42%

*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.

ADC Therapeutics SA
NYSE:ADCTUnited States

Search Criteria

Charts

Recent News

Nov 8, 2024

DJ ADC Therapeutics Initiated at Overweight by Stephens & Co., from 7:18AM ET on Friday Nov 08, 2024 by Dow Jones

Nov 7, 2024

Press Release: ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational Update, from 7:30AM ET on Thursday Nov 07, 2024 by Dow Jones

ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational Update, from 7:30AM ET on Thursday Nov 07, 2024 by Dow Jones

Nov 5, 2024

ADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual Meeting, from 9:48AM ET on Tuesday Nov 05, 2024 by Dow Jones

Nov 4, 2024

ADC Therapeutics to Present at November Investor Conferences, from 7:15AM ET on Monday Nov 04, 2024 by Dow Jones

Biotechnology Industry Peers

Company Information

Contact Information

Executives

Ratings

Reports

Fundamentals

Calendar